This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Suboxone (buprenorphine + naloxone)

Authoring team

  • combination buprenorphine and naloxone was introduced to help eliminate diversion and IV use of buprenorphine (1)
    • combination is supposed to have a lower IV abuse potential than buprenorphine alone
      • sublingual tablet combining buprenorphine and naloxone in a 4:1 ratio (Suboxone) has been developed (2)
        • taken as directed (sublingually), the naloxone component is not clinically active and so Suboxone is as efficacious as buprenorphine alone (3,4)
        • when injected the naloxone is clinically active and is likely to precipitate withdrawal in opioid-dependent patients (3)
      • however a survey of IV drug abusers revealed that 68% of the respondents had tried IV buprenorphine + naloxone and 66% of those who tried it, took it again or even regularly (1)
        • may indicate that combining naloxone with buprenorphine does not block all agonist effects when used IV
        • however, the continued usage of the combination product might reflect the fact that the study population was from a needle exchange program accustomed to using drugs IV, and the habit may not have been extinguished by a few non-reinforced attempts
          • this conclusion is supported by the finding that 80% reported that they had a 'bad' experience with the combination product, while less than 20% reported it 'similar' to experiences with IV buprenorphine
          • consistent with this finding, respondents were willing to pay a significantly higher street price for buprenorphine than for the combination product
        • the study authors concluded that treating heroin misuse with the combination buprenorphine + naloxone, could reduce the number using buprenorphine IV on the street (1)

Reference:

  1. Alho H et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2006.
  2. Bell J et al. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.Drug Alcohol Rev. 2004 Sep;23(3):311-7.
  3. Mendelson et al. Drug Alcohol Depend 2003;70:29-37.
  4. Fudula et al. New Engl J Med 2003;349:949-95.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.